Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US

Eric L. Ross(McLean Hospital), Steven E. Arnold(Massachusetts General Hospital)
JAMA Neurology
March 28, 2022
Cited by 128


Related Papers